JHVEPhoto Barron’s said this week that ResMed (NYSE:RMD) trades at a compelling valuation after the stock sold off last month in reaction to positive data for Eli Lilly’s (NYSE:LLY) GLP-1 therapy, tirzepatide, in obstructive sleep apnea, a condition targeted by the MedTech company. In late June, Lilly (LLY) said tirzepatide,Continue Reading
JHVEPhoto Eli Lilly (NYSE:LLY) said Friday it expects to report Q2 IPR&D pre-tax charges of around $154M, amounting to approximately $0.14 a share on a GAAP and non-GAAP basis, according to Bloomberg. Analysts were expecting Lilly to report Q2 GAAP EPS of $2.76 and non-GAAP EPS of $2.81. The drugmakerContinue Reading
The S&P 500’s health care sector (NYSEARCA:XLV), holding a weightage of 12.12% in the S&P 500 index, saw a fall of 0.49% in Q2 and is the fifth lowest scored sector by the SA Quant rating system. With earnings kicking off next week, we look at the sector’s performance andContinue Reading
jetcityimage/iStock Editorial via Getty Images Eli Lilly (NYSE:LLY) has named Gordon Brooks as its interim chief financial officer, effective July 15, 2024. Brooks has held various leadership roles during his 29-year career with the company, and currently serves as group VP, controller and corporate strategy. He will replace Anat Ashkenazi,Continue Reading
jetcityimage/iStock Editorial via Getty Images The U.S. FDA has approved Eli Lilly’s (NYSE:LLY) donanemab as a treatment for early Alzheimer’s disease. The therapy, which is given via infusion once a month, will be marketed under the name Kisunla. Lilly noted that the treatment will cost $12,522 over six months andContinue Reading
Alnylam Pharmaceuticals (NASDAQ:ALNY) was the best performing large cap ($30B+) pharma or biotech in Q2, returning ~58.5% in the period. The biotech’s strong performance was helped significantly in late June when it reported strong pivotal trial results for vutrisiran, a treatment for ATTR amyloidosis with cardiomyopathy, sending shares skyrocketing. FollowingContinue Reading
tylim Health Canada has authorized Eli Lilly’s atopic dermatitis treatment Ebglyss (lebrikizumab). The biologic is a first-line therapy for those 12 years and older. Ebglyss is given every four weeks, and trials showed that skin clearance and itch relief was seen as soon as four weeks. Ebglyss was approved inContinue Reading
JHVEPhoto Inspire Medical Systems (NYSE:INSP) and ResMed (NYSE:RMD) are both down significantly in Monday trading, apparent casualties of positive data released after the closing bell on June 21 of Eli Lilly’s (LLY) diabetes and weight loss drug tirzepatide as a sleep apnea treatment. Inspire manufactures an implantable neurostimulation device forContinue Reading
CR Eli Lilly (NYSE:LLY) and Novo Nordisk (NVO), which already have blockbusters with their weight loss drugs Zepbound (tirzepatide) and Wegovy (tirzepatide), are likely to dominate the market even if other drugs are approved, according to two Street analysts. Holly Morris, managing director at J.P. Morgan Asset Management focused onContinue Reading
